Trial Profile

Randomized, double-blind, Phase 2 study to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with moderate to severe active ulcerative colitis who have failed or are intolerant to previous treatment(s)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Aug 2026 According to an OSE Immunotherapeutics media release, the company will host a webcast with international experts in Inflammatory Bowel Diseases (IBD) to discuss promising results from the CoTiKis Phase 2 clinical trial in Ulcerative Colitis, future development plans in Chronic Pouchitis and will conclude with questions from the audience.
22 Jun 2025 Status changed from active, no longer recruiting to completed.
05 May 2025 According to an OSE Immunotherapeutics media release, Arnaud Bourreille is principal investigator of the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com